Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

56.47USD
30 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$56.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
610,394
52-wk High
$56.70
52-wk Low
$36.26

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.65
Market Cap (Mil.): $53,240.38
Shares Outstanding (Mil.): 953.28
Dividend: 0.34
Yield (%): 2.42

Financials

  TEVA.N Industry Sector
P/E (TTM): 18.61 32.70 33.67
EPS (TTM): 3.04 -- --
ROI: 7.47 18.12 17.39
ROE: 11.47 18.79 18.21
Search Stocks

UPDATE 2-Teva raises 2014 profit forecast after strong third quarter

* Raises 2014 EPS outlook to $5.00-$5.10 from pvs $4.90-$5.10

30 Oct 2014

Teva optimistic U.S. top court to rule in favor of MS drug patent

TEL AVIV - Teva Pharmaceutical Industries is optimistic the U.S. Supreme Court will decide in its favor regarding patent protection for Copaxone, its multiple sclerosis treatment, Chief Executive Erez Vigodman said on Thursday.

30 Oct 2014

Teva optimistic U.S. top court to rule in favour of MS drug patent

TEL AVIV, Oct 30 - Teva Pharmaceutical Industries is optimistic the U.S. Supreme Court will decide in its favour regarding patent protection for Copaxone, its multiple sclerosis treatment, Chief Executive Erez Vigodman said on Thursday.

30 Oct 2014

Teva Pharm Q3 profit beats estimates, raises 2014 EPS forecast

TEL AVIV, Oct 30 - Teva Pharmaceutical Industries reported quarterly profit that beat analysts' estimates on Thursday and raised its earnings forecast for the full year.

30 Oct 2014

UPDATE 2-U.S. top court divided in battle over Teva MS drug patent

(Adds fresh details from oral argument, paragraphs 8-9, 11-12)

15 Oct 2014

U.S. Supreme Court justices divided over Teva patent battle

WASHINGTON, Oct 15 - The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug.

15 Oct 2014

U.S. top court hears Teva's multiple sclerosis drug patent fight

WASHINGTON - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.

15 Oct 2014

U.S. top court hears Teva's multiple sclerosis drug patent fight

WASHINGTON, Oct 15 - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.

15 Oct 2014

Actavis to buy Durata in a deal valued at about $675 million

- Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.

06 Oct 2014

UPDATE 1-Actavis to buy Durata in a deal valued at about $675 mln

Oct 6 - Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.

06 Oct 2014

Competitors

  Price Change
Novartis AG (NOVN.VX) CHF88.95 +1.25
Biogen Idec Inc (BIIB.OQ) $321.00 --

Earnings vs. Estimates

Search Stocks